JP2008501760A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008501760A5 JP2008501760A5 JP2007526303A JP2007526303A JP2008501760A5 JP 2008501760 A5 JP2008501760 A5 JP 2008501760A5 JP 2007526303 A JP2007526303 A JP 2007526303A JP 2007526303 A JP2007526303 A JP 2007526303A JP 2008501760 A5 JP2008501760 A5 JP 2008501760A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- lower alkyl
- composition according
- unsubstituted
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 125000003118 aryl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- -1 methylpyrrolyl Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- XCVDGQBGMARFRY-GFCCVEGCSA-N (2r)-2-acetamido-n-[(3-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC(F)=C1 XCVDGQBGMARFRY-GFCCVEGCSA-N 0.000 claims 1
- PVNGTPGYSFGJIH-GFCCVEGCSA-N (2r)-2-acetamido-n-[(4-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=C(F)C=C1 PVNGTPGYSFGJIH-GFCCVEGCSA-N 0.000 claims 1
- SGBCQENKTXKIRD-MRXNPFEDSA-N (2r)-2-acetamido-n-benzyl-2-phenylacetamide Chemical compound O=C([C@H](NC(=O)C)C=1C=CC=CC=1)NCC1=CC=CC=C1 SGBCQENKTXKIRD-MRXNPFEDSA-N 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000003838 furazanyl group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000005518 mononeuropathy Diseases 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000030062 persistent idiopathic facial pain Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57806204P | 2004-06-09 | 2004-06-09 | |
| EP04013635A EP1604655A1 (en) | 2004-06-09 | 2004-06-09 | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| PCT/EP2005/006202 WO2005120539A2 (en) | 2004-06-09 | 2005-06-09 | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008501760A JP2008501760A (ja) | 2008-01-24 |
| JP2008501760A5 true JP2008501760A5 (enExample) | 2008-04-17 |
Family
ID=34925315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007526303A Withdrawn JP2008501760A (ja) | 2004-06-09 | 2005-06-09 | 三叉神経痛における疼痛を治療するためのペプチド化合物の新しい使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7820857B2 (enExample) |
| EP (2) | EP1604655A1 (enExample) |
| JP (1) | JP2008501760A (enExample) |
| CN (1) | CN1964708A (enExample) |
| AU (1) | AU2005251465B2 (enExample) |
| BR (1) | BRPI0511995A (enExample) |
| CA (1) | CA2565101A1 (enExample) |
| EA (1) | EA200602221A1 (enExample) |
| MX (1) | MXPA06014193A (enExample) |
| TW (1) | TW200701982A (enExample) |
| UA (1) | UA88169C2 (enExample) |
| WO (1) | WO2005120539A2 (enExample) |
| ZA (1) | ZA200608745B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE327744T1 (de) * | 2001-03-20 | 2006-06-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz |
| DE60100055T2 (de) | 2001-03-21 | 2003-07-24 | Schwarz Pharma Ag | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen |
| BRPI0417101A (pt) * | 2003-12-02 | 2007-02-06 | Sanol Arznei Schwarz Gmbh | uso de compostos de peptìdeo para tratamento de dor neuropática central |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| CN1950101B (zh) | 2004-04-16 | 2011-03-30 | 舒沃茨药物股份公司 | 肽化合物用于预防和治疗慢性头痛的用途 |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| MX2007002269A (es) * | 2004-08-27 | 2007-06-15 | Sanol Arznei Schwarz Gmbh | Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos. |
| EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| WO2007025286A2 (en) * | 2005-08-26 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
| CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| KR20150003925A (ko) | 2006-06-15 | 2015-01-09 | 유씨비 파르마 게엠베하 | 상승적 항경련 효과를 갖는 약제학적 조성물 |
| EP1873527A1 (en) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
| EP1920780A1 (en) * | 2006-10-12 | 2008-05-14 | Schwarz Pharma Ag | Peptide compounds for the treatment of hyperexcitability disorders |
| CA2774569A1 (en) | 2009-09-23 | 2011-03-31 | The University Of North Carolina At Chapel Hill | Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| PH12012500886A1 (en) * | 2009-11-03 | 2012-11-26 | Lupin Ltd | Modified release formulation of lacosamide |
| EP2468261A1 (en) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
| US20130251813A1 (en) | 2010-12-02 | 2013-09-26 | Ucb Pharma Gmbh | Formulation of lacosamide |
| PL3242676T3 (pl) | 2015-01-07 | 2024-07-15 | Tonix Pharma Limited | Preparaty oksytocyny zawierające magnez i sposoby ich stosowania |
| EP3397253A1 (en) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
| NZ787097A (en) | 2016-04-12 | 2025-10-31 | Tonix Pharma Ltd | Magnesium-containing oxytocin formulations and methods of use |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378729A (en) * | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| TW217417B (enExample) | 1991-12-04 | 1993-12-11 | Manyu Seiyaku Kk | |
| US5585358A (en) * | 1993-07-06 | 1996-12-17 | Yissum Research Development Corporation Of The Hebrew University Of Jerusalem | Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
| GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
| US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5849737A (en) | 1995-04-14 | 1998-12-15 | The Regents Of The University Of California | Compositions and methods for treating pain |
| JP4313435B2 (ja) * | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| US6114390A (en) * | 1995-11-30 | 2000-09-05 | Karl Thomae Gmbh | Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
| DE19544687A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US6037324A (en) * | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| GB9601724D0 (en) * | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| US5773475A (en) * | 1997-03-17 | 1998-06-30 | Research Corporation Technologies, Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| US6277825B1 (en) * | 1996-07-22 | 2001-08-21 | University Of Utah Research Foundation | Use of conantokins for treating pain |
| US6001876A (en) * | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
| US6589994B1 (en) | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
| US6048899A (en) * | 1997-03-17 | 2000-04-11 | Research Corporation Tech., Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| ATE320249T1 (de) | 1997-07-08 | 2006-04-15 | Ono Pharmaceutical Co | Aminosäurederivate |
| US6737408B1 (en) * | 1997-08-07 | 2004-05-18 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| AU7696098A (en) | 1997-08-11 | 1999-03-01 | Algos Pharmaceutical Corporation | Substance p inhibitors in combination with nmda-blockers for treating pain |
| US6492553B1 (en) * | 1998-01-29 | 2002-12-10 | Aventis Pharamaceuticals Inc. | Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds |
| US6673832B1 (en) | 1998-05-04 | 2004-01-06 | Gudarz Davar | Methods for identifying compounds for treating pain |
| US7427602B1 (en) * | 1998-05-13 | 2008-09-23 | The Regents Of The University Of Michigan | Sustained DNA delivery from structural matrices |
| GB9816228D0 (en) | 1998-07-24 | 1998-09-23 | Pfizer Ltd | Isoquinolines |
| JP2002527378A (ja) | 1998-10-15 | 2002-08-27 | インペリアル・カレッジ・イノベイションズ・リミテッド | 治療方法 |
| CA2361402C (en) | 1999-09-03 | 2009-05-12 | Actelion Pharmaceuticals Ltd | Bis-sulfonamides |
| SE0001373D0 (sv) | 2000-04-13 | 2000-04-13 | Karolinska Innovations Ab | NPY Y1 receptor agonists and antagonists |
| CA2348847A1 (en) | 2000-05-31 | 2001-11-30 | Pfizer Inc. | New isoxazole-sulfonamide endothelin antagonists |
| US6727226B2 (en) * | 2000-07-21 | 2004-04-27 | University Of Utah Research Foundation | Mu-conopeptides |
| SI1311256T1 (sl) * | 2000-08-17 | 2005-12-31 | Teva Pharma | Uporaba derivatov amidov valprojske kisline in amidov 2-valproenske kisline za zdravljenje ali preprecevanje bolecin in/ali glavobolnih motenj |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| ES2435000T3 (es) | 2000-08-25 | 2013-12-18 | Research Corporation Technologies, Inc. | Aminoácidos anticonvulsionantes para el tratamiento del dolor |
| US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| WO2002042256A2 (en) | 2000-11-21 | 2002-05-30 | Ucb, S.A. | N-alkylated gaba compounds, processes for their preparation and their use as medicaments |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| CA2434495A1 (en) | 2001-01-30 | 2002-08-08 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| ATE327744T1 (de) * | 2001-03-20 | 2006-06-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz |
| DE60100055T2 (de) | 2001-03-21 | 2003-07-24 | Schwarz Pharma Ag | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen |
| IL157093A0 (en) | 2001-03-27 | 2004-02-08 | Actelion Pharmaceuticals Ltd | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| ITMI20011308A1 (it) | 2001-06-21 | 2002-12-21 | Nicox Sa | Farmaci per il dolore cronico |
| FR2831820B1 (fr) | 2001-11-05 | 2004-08-20 | Ethypharm Sa | Comprime orodispersible presentant une grande homogeneite et son procede de preparation |
| WO2003099338A2 (en) * | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| CA2505361A1 (en) | 2002-11-11 | 2004-05-27 | Bayer Healthcare Ag | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist |
| US7687080B2 (en) * | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040209960A1 (en) | 2003-01-30 | 2004-10-21 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using sodium channell modulators |
| US20040213842A1 (en) | 2003-01-30 | 2004-10-28 | Dynogen Pharmaceuticals, Inc. | Methods of treating gastrointestinal tract disorders using sodium channel modulators |
| WO2004100871A2 (en) | 2003-05-09 | 2004-11-25 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a renin inhibitor |
| US20070208166A1 (en) | 2003-10-24 | 2007-09-06 | Exelixis, Inc. | Tao Kinase Modulators And Method Of Use |
| EP1537862A1 (en) | 2003-12-02 | 2005-06-08 | Schwarz Pharma Ag | Novel use of peptide compounds for treating central neuropathic pain |
| BRPI0417101A (pt) * | 2003-12-02 | 2007-02-06 | Sanol Arznei Schwarz Gmbh | uso de compostos de peptìdeo para tratamento de dor neuropática central |
| EP1541138A1 (en) | 2003-12-05 | 2005-06-15 | Schwarz Pharma Ag | Novel use of peptide compounds for treating status epilepticus or related conditions |
| US20060009384A1 (en) * | 2003-12-05 | 2006-01-12 | David Rudd | Novel use of peptide compounds for treating status epilepticus or related conditions |
| US20100256179A1 (en) | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| EP1579858A1 (en) | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| US20050227961A1 (en) * | 2004-04-08 | 2005-10-13 | Vela Pharmaceuticals, Inc. | Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome |
| CN1950101B (zh) * | 2004-04-16 | 2011-03-30 | 舒沃茨药物股份公司 | 肽化合物用于预防和治疗慢性头痛的用途 |
| EP1604654A1 (en) * | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating dyskinesia |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| EP1604656A1 (en) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| MX2007002269A (es) * | 2004-08-27 | 2007-06-15 | Sanol Arznei Schwarz Gmbh | Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos. |
| EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
| EP1688137A1 (en) | 2005-01-28 | 2006-08-09 | Schwarz Pharma Ag | SPM 927 for add-on therapy of schizophrenia |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| EP1754476A1 (en) | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| EP1873527A1 (en) | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
| KR20150003925A (ko) | 2006-06-15 | 2015-01-09 | 유씨비 파르마 게엠베하 | 상승적 항경련 효과를 갖는 약제학적 조성물 |
| WO2009053070A1 (en) | 2007-10-23 | 2009-04-30 | Schwarz Pharma Ag | Compounds for treating demyelination conditions |
-
2004
- 2004-06-09 EP EP04013635A patent/EP1604655A1/en not_active Withdrawn
-
2005
- 2005-06-09 CA CA002565101A patent/CA2565101A1/en not_active Abandoned
- 2005-06-09 MX MXPA06014193A patent/MXPA06014193A/es not_active Application Discontinuation
- 2005-06-09 US US11/148,429 patent/US7820857B2/en not_active Expired - Fee Related
- 2005-06-09 JP JP2007526303A patent/JP2008501760A/ja not_active Withdrawn
- 2005-06-09 BR BRPI0511995-2A patent/BRPI0511995A/pt not_active IP Right Cessation
- 2005-06-09 UA UAA200700160A patent/UA88169C2/ru unknown
- 2005-06-09 WO PCT/EP2005/006202 patent/WO2005120539A2/en not_active Ceased
- 2005-06-09 EP EP05754667.3A patent/EP1753415B1/en not_active Expired - Lifetime
- 2005-06-09 CN CNA2005800185740A patent/CN1964708A/zh active Pending
- 2005-06-09 AU AU2005251465A patent/AU2005251465B2/en not_active Ceased
- 2005-06-09 EA EA200602221A patent/EA200602221A1/ru unknown
- 2005-07-11 TW TW094123448A patent/TW200701982A/zh unknown
-
2006
- 2006-10-19 ZA ZA200608745A patent/ZA200608745B/en unknown
-
2010
- 2010-06-16 US US12/816,753 patent/US8338641B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008501760A5 (enExample) | ||
| JP2008501753A5 (enExample) | ||
| JP2008503533A5 (enExample) | ||
| JP2007530493A5 (enExample) | ||
| JP2007532607A5 (enExample) | ||
| CA2566301A1 (en) | Novel use of peptide compounds for treating essential tremor and other tremor syndromes | |
| CN103997894B (zh) | 乳癌的治疗 | |
| ES2217191T5 (es) | Asociacion de un antagonista del receptor cb1 y de sibutramina para el tratamiento de la obesidad. | |
| JP2008510758A5 (enExample) | ||
| US8759400B2 (en) | Histone deacetylase inhibitors for enhancing activity of antifungal agents | |
| JP2004519469A5 (enExample) | ||
| US20090018198A1 (en) | Method for treating a motoneuron disorder | |
| JP2015503540A5 (enExample) | ||
| JP2009545521A5 (enExample) | ||
| LU91512I2 (fr) | "Lacosamide et ses dérivés pharmaceutiquement acceptables (VIMPATr)" | |
| JP2010530431A5 (enExample) | ||
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2012515184A5 (enExample) | ||
| CA2652048A1 (en) | Method and compositions for treating hematological malignancies | |
| JP2014516942A5 (enExample) | ||
| JP2015510908A (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| JP2019515884A5 (enExample) | ||
| JP2013535422A5 (enExample) | ||
| ES2704229T3 (es) | Agonistas selectivos del receptor AT2 para su uso en el tratamiento de la caquexia | |
| US20230000866A1 (en) | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |